Tomivosertib (eFT508) is a highly selective, potent dual inhibitor of MNK1 and MNK2 kinases, exhibiting IC50 values in the low nanomolar range. It is widely used in preclinical research to investigate MNKs role in oncogenesis and immune modulation, demonstrating antitumor activity in both cellular assays and in vivo animal models.